Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity

Autores
Fraunhoffer Navarro, Nicolas Alejandro; Meilerman Abuelafia, Analía; Chanez, Brice; Bigonnet, Martin; Gayet, Odile; Roques, Julie; Chuluyan, Hector Eduardo; Dusetti, Nelson; Iovanna, Juan Lucio
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity.
Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Meilerman Abuelafia, Analía. Inserm; Francia
Fil: Chanez, Brice. Inserm; Francia
Fil: Bigonnet, Martin. Inserm; Francia
Fil: Gayet, Odile. Inserm; Francia
Fil: Roques, Julie. Inserm; Francia
Fil: Chuluyan, Hector Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Dusetti, Nelson. Inserm; Francia
Fil: Iovanna, Juan Lucio. Inserm; Francia
Materia
CANCER DE PANCREAS
FOLFIRINOX
GEMCITABINE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/214158
Acceder
id CONICETDig_8f9c22702bb21a2a13119310be3da977
oai_identifier_str oai:ri.conicet.gov.ar:11336/214158
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activityFraunhoffer Navarro, Nicolas AlejandroMeilerman Abuelafia, AnalíaChanez, BriceBigonnet, MartinGayet, OdileRoques, JulieChuluyan, Hector EduardoDusetti, NelsonIovanna, Juan LucioCANCER DE PANCREASFOLFIRINOXGEMCITABINEhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity.Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Meilerman Abuelafia, Analía. Inserm; FranciaFil: Chanez, Brice. Inserm; FranciaFil: Bigonnet, Martin. Inserm; FranciaFil: Gayet, Odile. Inserm; FranciaFil: Roques, Julie. Inserm; FranciaFil: Chuluyan, Hector Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; ArgentinaFil: Dusetti, Nelson. Inserm; FranciaFil: Iovanna, Juan Lucio. Inserm; FranciaWiley2022-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/214158Fraunhoffer Navarro, Nicolas Alejandro; Meilerman Abuelafia, Analía; Chanez, Brice; Bigonnet, Martin; Gayet, Odile; et al.; Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity; Wiley; Cancer Communications; 42; 11; 9-2022; 1212-12162523-35482523-3548CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/cac2.12365info:eu-repo/semantics/altIdentifier/doi/10.1002/cac2.12365info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:14:23Zoai:ri.conicet.gov.ar:11336/214158instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:14:24.029CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
title Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
spellingShingle Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Fraunhoffer Navarro, Nicolas Alejandro
CANCER DE PANCREAS
FOLFIRINOX
GEMCITABINE
title_short Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
title_full Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
title_fullStr Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
title_full_unstemmed Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
title_sort Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
dc.creator.none.fl_str_mv Fraunhoffer Navarro, Nicolas Alejandro
Meilerman Abuelafia, Analía
Chanez, Brice
Bigonnet, Martin
Gayet, Odile
Roques, Julie
Chuluyan, Hector Eduardo
Dusetti, Nelson
Iovanna, Juan Lucio
author Fraunhoffer Navarro, Nicolas Alejandro
author_facet Fraunhoffer Navarro, Nicolas Alejandro
Meilerman Abuelafia, Analía
Chanez, Brice
Bigonnet, Martin
Gayet, Odile
Roques, Julie
Chuluyan, Hector Eduardo
Dusetti, Nelson
Iovanna, Juan Lucio
author_role author
author2 Meilerman Abuelafia, Analía
Chanez, Brice
Bigonnet, Martin
Gayet, Odile
Roques, Julie
Chuluyan, Hector Eduardo
Dusetti, Nelson
Iovanna, Juan Lucio
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CANCER DE PANCREAS
FOLFIRINOX
GEMCITABINE
topic CANCER DE PANCREAS
FOLFIRINOX
GEMCITABINE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity.
Fil: Fraunhoffer Navarro, Nicolas Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Meilerman Abuelafia, Analía. Inserm; Francia
Fil: Chanez, Brice. Inserm; Francia
Fil: Bigonnet, Martin. Inserm; Francia
Fil: Gayet, Odile. Inserm; Francia
Fil: Roques, Julie. Inserm; Francia
Fil: Chuluyan, Hector Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
Fil: Dusetti, Nelson. Inserm; Francia
Fil: Iovanna, Juan Lucio. Inserm; Francia
description Pancreatic ductal adenocarcinoma (PDAC) treatmentis focused on two regimens. The polychemotherapy, FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxali-platin), is used in patients with good health conditions, while gemcitabine, as monotherapy, in patients withpoor health conditions. Gemcitabine resistance-associated pathways have been targeted to sensitize cancercells, but the results were disappointing. Using a transcrip-tomic bioinformatics analysis combined with biologicalvalidation, we showed that glucuronidation was associated with the gemcitabine resistance in PDAC, and its inhibition could switch tumors from resistant to sensitive.To unravel the biological drivers of gemcitabineresponse in PDAC, we determined the transcriptomic dissimilarity between two preclinical models with definedgemcitabine sensitivity.
publishDate 2022
dc.date.none.fl_str_mv 2022-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/214158
Fraunhoffer Navarro, Nicolas Alejandro; Meilerman Abuelafia, Analía; Chanez, Brice; Bigonnet, Martin; Gayet, Odile; et al.; Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity; Wiley; Cancer Communications; 42; 11; 9-2022; 1212-1216
2523-3548
2523-3548
CONICET Digital
CONICET
url http://hdl.handle.net/11336/214158
identifier_str_mv Fraunhoffer Navarro, Nicolas Alejandro; Meilerman Abuelafia, Analía; Chanez, Brice; Bigonnet, Martin; Gayet, Odile; et al.; Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity; Wiley; Cancer Communications; 42; 11; 9-2022; 1212-1216
2523-3548
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/cac2.12365
info:eu-repo/semantics/altIdentifier/doi/10.1002/cac2.12365
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614070815162368
score 13.070432

Publicaciones similares